Abstract
Purpose
To semiquantify the uptake of N-isopropyl-p-[123I]-iodoamphetamine (I-123 IMP) in patients with uveal malignant melanoma reproducibly and objectively.
Methods
Fifty-two patients were examined. Twenty-nine patients had malignant melanoma (group A), three were clinically diagnosed with metastatic choroidal tumor, and 20 patients were given either histological or clinical diagnoses of either benign pigmented lesion or tumor (group B). Early and delayed I-123 IMP images were obtained and standardized by Neurostat software. Using fusion software, we applied a three-dimensional region of interest (3D-ROI) template to the standardized I-123 IMP, and calculated the retention index and tumor-to-nontumor (T/N) ratio of the delayed phase using the maximum count for each ROI.
Results
Sensitivity at the retention index cutoff of 30 was 82.4%, specificity was 85.2%, and accuracy was 83.6%. Sensitivity at the T/N ratio of the delayed phase cutoff of 1.3 was 91.2%, specificity was 77.8%, and accuracy was 85.2%. The positive predictive value of the T/N ratio was better than that of the retention index. The negative predictive value of the retention index was better than that of the T/N ratio.
Conclusion
This new semiquantitative estimation method is reproducible and objective, especially when the examinations are performed repeatedly for evaluation of both therapy and follow-up.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sou R, Oku N, Ohguro N, Hibino S, Fujikado T, Tano Y. The clinical role of N-isopropyl-p-[123I]-iodoamphetamine single photon emission computed tomography in the follow-up of choroidal melanoma after radiotherapy. Jpn J Ophthalmol 2004;48:54–58.
Morimoto K, Yoshimura M, Goto H, Koizumi K, Abe K. Semiquantitative evaluation of uveal malignant melanoma with Nisopropyl-p-[123I]-iodoamphetamine (I-123 IMP). J Tokyo Med Univ 2007;65:137–143.
Goto H. Clinical efficacy of I-123 IMP SPECT for the diagnosis of malignant uveal melanoma. Int J Clin Oncol 2004;9:74–78.
Kotake F, Kawanishi M, Ishii I, Akata S, Kakizaki D, Abe K. A case of choroidal malignant melanoma in which I-123 IMP scintigraphy was useful for diagnosis. Kaku Igaku 1998;35:427–433.
Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 1994;35:1528–1537.
Minoshima S, Koeppe RA, Mintun MA, et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med 1993;34:322–329.
Prichard RS, Hill AD, Skehan SJ, O’Higgins N. Positron emission tomography for staging and management of malignant melanoma. Br J Surg 2002;89:389–396.
Kato K, Kubota T, Ikeda M, et al. Low efficacy of 18F-FDG PET for detection of uveal malignant melanoma compared with 123IIMP SPECT. J Nucl Med 2006;47:404–409.
Murata K, Suzuki K, Ayakawa Y, Higashi N, Lin PP. Comparison of I-123 IMP and Ga-67 citrate scintigraphy of malignant melanoma. Clin Nucl Med 2003;28:704–708.
Watanabe M, Seto H, Yokoyama K, et al. Scintigraphic study of malignant melanoma with I-123 iodoamphetamine. Nucl Med Commun 1996;17:153–159.
Satoh M, Ishikawa N, Takeda T, et al. Clinical assessment of I-123 IMP scintigraphy in malignant melanoma. Jpn J Clin Radiol 1991;36:913–918.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yoshimura, M., Kanesaka, N., Saito, K. et al. Diagnosis of uveal malignant melanoma by a new semiquantitative assessment of N-isopropyl-p-[123I]-iodoamphetamine. Jpn J Ophthalmol 55, 148–154 (2011). https://doi.org/10.1007/s10384-010-0915-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-010-0915-9